C
Cagricema
Productby Novo Nordisk
Heard in 4 episodes across 3 shows since Sep 2026
CagriSema is an investigational once-weekly fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a GLP-1 receptor agonist. It is being developed to support weight management and treatment of type 2 diabetes by reducing body weight and improving glycemic control.
Episodes
4
across 3 shows
First heard
Sep 2026
Episodes per month
Public PodLume episodes featuring it, over the last year.
1
1
2
Show the data
| Month | Episodes |
|---|---|
| Dec 2025 | 0 |
| Jan 2026 | 0 |
| Feb 2026 | 0 |
| Mar 2026 | 0 |
| Apr 2026 | 0 |
| May 2026 | 0 |
| Jun 2026 | 0 |
| Jul 2026 | 0 |
| Aug 2026 | 0 |
| Sep 2026 | 1 |
| Oct 2026 | 1 |
| Nov 2026 | 2 |
Email alert
Email me when Cagricema comes up on a podcast
One email a week at most, with the new episodes that mention Cagricema. Free, no account needed, unsubscribe in one click.
Episodes
4 episodes featuring Cagricema, newest first
- Nov 4, 2026
Markets rally as Democrats take CongressCNBC's "Fast Money"Nov 4, 2026 - Nov 1, 2026
Investors test Novo, Moody’s, and Deckers against bear casesThe Investor's Podcast (We Study Billionaires) - The Investor’s Podcast NetworkNov 1, 2026 - Oct 20, 2026
Markets weigh Netflix weakness against AI infrastructure ambitionsCNBC's "Fast Money"Oct 20, 2026 - Sep 21, 2026
Paramount clears key obstacle to Warner acquisitionWSJ What’s NewsSep 21, 2026